Sp12

ADVANCES IN DIAGNOSTICS AND WORKUP FOR GERD

Date
May 6, 2023
Explore related products in the following collection:

Society: DDW

LIVE STREAM SESSION

Presenter

Speaker Image for Amber Shada
University of Wisconsin Hospitals and Clinics

Tracks

Related Products

Thumbnail for MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
Thumbnail for GLIAL CONNEXIN-43 HEMICHANNELS ARE CRITICAL DETERMINANTS OF GUT INFLAMMATION IN MOUSE POSTOPERATIVE ILEUS AND REACTIVE HUMAN ENTERIC GLIA
GLIAL CONNEXIN-43 HEMICHANNELS ARE CRITICAL DETERMINANTS OF GUT INFLAMMATION IN MOUSE POSTOPERATIVE ILEUS AND REACTIVE HUMAN ENTERIC GLIA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
SOCIETY: DDW
Thumbnail for IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…